CA3233220A1 - Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta - Google Patents
Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta Download PDFInfo
- Publication number
- CA3233220A1 CA3233220A1 CA3233220A CA3233220A CA3233220A1 CA 3233220 A1 CA3233220 A1 CA 3233220A1 CA 3233220 A CA3233220 A CA 3233220A CA 3233220 A CA3233220 A CA 3233220A CA 3233220 A1 CA3233220 A1 CA 3233220A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- sclerostin antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250918P | 2021-09-30 | 2021-09-30 | |
| US63/250,918 | 2021-09-30 | ||
| US202263374982P | 2022-09-08 | 2022-09-08 | |
| US63/374,982 | 2022-09-08 | ||
| PCT/US2022/077259 WO2023056355A2 (en) | 2021-09-30 | 2022-09-29 | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233220A1 true CA3233220A1 (en) | 2023-04-06 |
Family
ID=85783647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233220A Pending CA3233220A1 (en) | 2021-09-30 | 2022-09-29 | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250011407A1 (https=) |
| EP (1) | EP4408884A4 (https=) |
| JP (1) | JP2024536106A (https=) |
| KR (1) | KR20240082380A (https=) |
| AU (1) | AU2022357544A1 (https=) |
| CA (1) | CA3233220A1 (https=) |
| MX (1) | MX2024003828A (https=) |
| TW (1) | TW202323278A (https=) |
| WO (1) | WO2023056355A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011517672A (ja) * | 2008-03-24 | 2011-06-16 | アボツト・バイオテクノロジー・リミテツド | 骨損失を治療するための方法及び組成物 |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| KR20190037261A (ko) * | 2016-08-08 | 2019-04-05 | 암젠 인크 | 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법 |
| MX2019007161A (es) * | 2016-12-21 | 2020-02-12 | Mereo Biopharma 3 Ltd | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. |
| US10961305B2 (en) * | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| GB201810746D0 (en) * | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
-
2022
- 2022-09-29 AU AU2022357544A patent/AU2022357544A1/en active Pending
- 2022-09-29 EP EP22877568.0A patent/EP4408884A4/en active Pending
- 2022-09-29 JP JP2024518919A patent/JP2024536106A/ja active Pending
- 2022-09-29 KR KR1020247013976A patent/KR20240082380A/ko active Pending
- 2022-09-29 US US18/696,578 patent/US20250011407A1/en active Pending
- 2022-09-29 WO PCT/US2022/077259 patent/WO2023056355A2/en not_active Ceased
- 2022-09-29 MX MX2024003828A patent/MX2024003828A/es unknown
- 2022-09-29 CA CA3233220A patent/CA3233220A1/en active Pending
- 2022-09-30 TW TW111137296A patent/TW202323278A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024536106A (ja) | 2024-10-04 |
| EP4408884A2 (en) | 2024-08-07 |
| TW202323278A (zh) | 2023-06-16 |
| AU2022357544A1 (en) | 2024-04-11 |
| MX2024003828A (es) | 2024-05-10 |
| US20250011407A1 (en) | 2025-01-09 |
| WO2023056355A2 (en) | 2023-04-06 |
| EP4408884A4 (en) | 2025-04-23 |
| KR20240082380A (ko) | 2024-06-10 |
| WO2023056355A3 (en) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12582712B2 (en) | Method of making anti-pro/latent myostatin antibodies | |
| US11925683B2 (en) | Compositions for making and using anti-Myostatin antibodies | |
| JP6353500B2 (ja) | Ｄｋｋ１抗体およびその使用方法 | |
| CA2682212C (en) | Anti-sclerostin antibodies | |
| CN111196849A (zh) | 抗硬骨素抗体、其抗原结合片段及其医药用途 | |
| US20250011407A1 (en) | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta | |
| WO2018115879A1 (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| CN117730095A (zh) | 中度至重度成骨不全症的治疗 | |
| WO2023017149A1 (en) | Thioredoxin 1 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240910 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240910 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240910 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |